Skip to main content
. Author manuscript; available in PMC: 2018 Feb 27.
Published in final edited form as: Stroke. 2016 Jun 2;47(7):1817–1824. doi: 10.1161/STROKEAHA.116.012995

Figure 1.

Figure 1

A–D, Change of clinical outcome end points from baseline for pooled SB623 cells at 12 months (intent-to-treat population, n=18). (A) European Stroke Scale. (B) National Institutes of Health Stroke Scale. (C) Fugl-Meyer (F-M) total score. (D) F-M motor function total score. Error bars represent SEM. P values represent significance of change vs baseline using the Wilcoxon signed-rank test (P<0.05), which were not corrected for multiplicity.